Status: Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.
Participants needed: 60
Trial details
Phase: Phase 2Age: 14+Biological sex: AllType: InterventionalSponsor: WestVac Biopharma Co., Ltd.Updated: Jan 30, 2026Locations: 7
Eligibility criteria
Age: 14 years through 65 years of age, male or female [+6]
Those who cannot take delamanid, bedaquiline, or linezolid for various reasons [+34]